‘Advanced simplicity’ will drive growth for inhalers in emerging markets, Peter Schmelzer, CEO of H&T Presspart tells us more.
The number of blockbuster respiratory products going off-patent has opened up opportunities for generic inhalers, and demand for asthma and chronic obstructive pulmonary disease (COPD) treatments is on the rise in the developing world, not just the mature markets.